Bristol-Myers Squibb
Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMY
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.
BMY Key Statistics
Stock Snapshot
The current Bristol-Myers Squibb(BMY) stock price is $51.75, with a market capitalization of 105.24B. The stock trades at a price-to-earnings (P/E) ratio of 17.61 and offers a dividend yield of 4.8%.
During the trading session on 2025-12-09, Bristol-Myers Squibb(BMY) shares reached a daily high of $51.75 and a low of $51.67. At a current price of $51.75, the stock is +0.2% higher than the low and still 0.0% under the high.
Trading activity shows a volume of 3.21K, compared to an average daily volume of 16.47M.
Over the past 52 weeks, Bristol-Myers Squibb(BMY) stock has traded between a high of $63.33 and a low of $42.52.
Over the past 52 weeks, Bristol-Myers Squibb(BMY) stock has traded between a high of $63.33 and a low of $42.52.
BMY News
Bristol Myers Squibb Co. (Symbol: BMY) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a whopping $18.88B worth of stock held by ETFs, and a...
Bristol Myers Squibb Co. (Symbol: BMY) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-averagestati...
Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Low PE Investor m...
Analyst ratings
70%
of 30 ratingsMore BMY News
Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb. The associated price target remains the same with $36.00. Tip...
Bristol Myers Squibb & Co. (NYSE:BMY) on Wednesday said it would enroll additional patients in the ADEPT-2 Phase 3 study. BMY shares are climbing with convicti...
In its recent Q3 2025 update, BioNTech reported a net loss largely tied to a contractual dispute settlement but raised full-year revenue guidance, supported by...
Bristol-Myers Squibb (BMY) has been drifting lately, with the share price down over the past year but ticking higher in the past month, and that contrast is cat...
